152 related articles for article (PubMed ID: 19542881)
1. Gene therapy for hemophilia A. Friend or foe?
Lippi G; Franchini M; Saenko EL
Blood Coagul Fibrinolysis; 2009 Sep; 20(6):395-9. PubMed ID: 19542881
[No Abstract] [Full Text] [Related]
2. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy for haemophilia.
Pasi KJ
Baillieres Clin Haematol; 1996 Jun; 9(2):305-17. PubMed ID: 8800507
[No Abstract] [Full Text] [Related]
4. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Hebbel RP; Galipeau J; Hough C; Lillicrap D
Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy for hemophilia.
Lynch CM
Curr Opin Mol Ther; 1999 Aug; 1(4):493-9. PubMed ID: 11713765
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Adeno-Associated Viral Vector-Mediated Human Factor VIII Gene Therapy in Hemophilia A Mice.
Greig JA; Wang Q; Reicherter AL; Chen SJ; Hanlon AL; Tipper CH; Clark KR; Wadsworth S; Wang L; Wilson JM
Hum Gene Ther; 2017 May; 28(5):392-402. PubMed ID: 28056565
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy for haemophilia: prospects and challenges to prevent or reverse inhibitor formation.
Scott DW; Lozier JN
Br J Haematol; 2012 Feb; 156(3):295-302. PubMed ID: 22055221
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
[TBL] [Abstract][Full Text] [Related]
9. Toward gene therapy for hemophilia A with novel adenoviral vectors: successes and limitations in canine models.
Arruda VR
J Thromb Haemost; 2006 Jun; 4(6):1215-7. PubMed ID: 16706962
[No Abstract] [Full Text] [Related]
10. State and prospects of gene therapy for the hemophilias.
Fallaux FJ; Hoeben RC; Briët E
Thromb Haemost; 1995 Jul; 74(1):266-73. PubMed ID: 8578470
[No Abstract] [Full Text] [Related]
11. Sustained phenotypic correction of hemophilia a mice following oncoretroviral-mediated expression of a bioengineered human factor VIII gene in long-term hematopoietic repopulating cells.
Moayeri M; Ramezani A; Morgan RA; Hawley TS; Hawley RG
Mol Ther; 2004 Nov; 10(5):892-902. PubMed ID: 15509507
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
[TBL] [Abstract][Full Text] [Related]
13. Sustained expression of human factor VIII in mice using a parvovirus-based vector.
Chao H; Mao L; Bruce AT; Walsh CE
Blood; 2000 Mar; 95(5):1594-9. PubMed ID: 10688813
[TBL] [Abstract][Full Text] [Related]
14. Animal testing of retroviral-mediated gene therapy for factor VIII deficiency.
Greengard JS; Jolly DJ
Thromb Haemost; 1999 Aug; 82(2):555-61. PubMed ID: 10605751
[No Abstract] [Full Text] [Related]
15. Impact of recombinant factor VIII on hemophilia care.
Mannucci PM
Vox Sang; 1994; 67 Suppl 3():49-52. PubMed ID: 7975511
[No Abstract] [Full Text] [Related]
16. Gene transfer as an approach to treating hemophilia.
High KA
Circ Res; 2001 Feb; 88(2):137-44. PubMed ID: 11157664
[TBL] [Abstract][Full Text] [Related]
17. Haemophilia A gene therapy.
Connelly S; Kaleko M
Haemophilia; 1998 Jul; 4(4):380-8. PubMed ID: 9873758
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the biological differences of canine and human factor VIII in gene delivery: implications in human hemophilia treatment.
Wang Q; Dong B; Firrman J; Wu W; Roberts S; Moore AR; Liu LS; Chin MP; Diao Y; Kost J; Xiao W
Gene Ther; 2016 Jul; 23(7):597-605. PubMed ID: 27064790
[TBL] [Abstract][Full Text] [Related]
19. Comments on the development of inhibitor antibodies in patients using recombinant factor VIII concentrates.
Brettler DB
Semin Hematol; 1991 Apr; 28(2 Suppl 1):45-6. PubMed ID: 1908128
[No Abstract] [Full Text] [Related]
20. Dual vectors expressing murine factor VIII result in sustained correction of hemophilia A mice.
Mah C; Sarkar R; Zolotukhin I; Schleissing M; Xiao X; Kazazian HH; Byrne BJ
Hum Gene Ther; 2003 Jan; 14(2):143-52. PubMed ID: 12614565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
